ACKC is a grassroots organization established in 2003 by kidney cancer patients and their families/caregivers who are working to raise awareness of kidney cancer and to ensure that it receives the public and private funding required to identify and develop effective treatment modalities and to find a cure for this disease. More >


  • 2014 ACKC Campaign for Research Funding

    April 24th, 2014 Staff

    ACKC is initiating its annual campaign to get a $15 million appropriation for kidney cancer research as part of the Congressionally Directed Medical Research Programs of the Department of Defense. The Dear Colleague Letter is signed by Senator Charles Schumer (D-NY) and Representative Peter King (R-NY) and Representative Carolyn McCarthy (D-NY).

    To send an automated letter to your senators and representative asking them to support this essential research funding, click here: Send a Letter.

    To see accomplishments of previous years’ campaigns, click Awards.

  • A look at IL-15 and IL-2

    April 25th, 2012 Chris Battle, survivor

    IL-15 is a cousin of IL-2, but it is believed to be more targeted than the latter. Both drugs are immunotherapeutic,attempting to kickstart the body’s natural immune system into fighting the cancer naturally. Each tries to increase and activate lymphocyites which house Natural Kill Cells. I’m not making this up; Natural Killer Cellsis actually what they are called. And although they sound like murderous psychotics, and to some degree they are, they are on our side. Like the body’s own mob hit men.

  • IL-15: A new immunotherapy trial for kidney cancer patients

    April 18th, 2012 Chris Battle, survivor

    Kidney cancer patient Chris Battle shares his experiences as he undergoes a new Phase I trial with the drug IL-15.

See All


  • GlaxoSmithKline liberalizes release of clinical trial data GlaxoSmithKline announced today, 10/11/2012, that they will make all clinical trial data available to researchers in their effort to become a more transparent company. This move could have a positive effect on clinical oncology practice. More >

  • Dr. Janice Dutcher Moves Offices Dr. Janice Dutcher has moved her clinical practice and IL-2 treatment program from the Montefiore Medical Center in the Bronx to the St. Luke’s Roosevelt Hospital Center in Manhattan where Dr. Dutcher is the Director of the Immunotherapy Program. More >